Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ISCT Annual Meeting

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) — Senti Bio, a leading gene circuit company, today announced presentations on its gene circuit engineered allogeneic CAR-NK cell therapy pipeline at the International Society for Cell and Gene Therapy (ISCT) Virtual Annual Meeting. The presentations provide details of Senti Bio’s process for manufacturing allogeneic CAR-NK cells. A key advantage of allogeneic cell therapies, versus autologous products that use each patient’s own cells, is the ability to potentially manufacture large batches of drug product from healthy donor cells that can be produced in advance of clinical use and then stored in frozen vials—thereby being broadly accessible in an off-the-shelf manner to cancer patients. Taken together, these abstracts support the development of processes for large scale production of “off-the-shelf” peripheral blood mononuclear cell (PBMC)-derived and umbilical cord blood (UCB)-derived CAR-NK cell-based therapies.

Senti Bio is designing gene circuits to enable a new generation of “smarter medicines” to potentially enhance the therapeutic effectiveness of cell and gene therapies against a broad range of diseases that cannot be readily addressed by current standards of care.

Click the button below to read the entire Press Release:

Continue Reading The Press Release